Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16579394 | 1.00 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL7912832 | 1.00 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL16579360 | 1.00 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL7919683 | 1.00 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL22679988 | 0.89 | MAPT (0.44) | MAPTPKMMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL22491857 | 0.88 | MAPT (0.47) | MAPTPKMSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9087268 | 0.83 | MEN1 (0.46) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL19048799 | 0.83 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL68965 | 0.83 | MEN1 (0.46) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL29277719 | 0.81 | MEN1 (0.37) | MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192833-B1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2026-01-21 | — | — | EP | disclosed |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2025-11-18 | — | — | US | disclosed |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2023-09-14 | — | — | US | disclosed |
| EP-4192833-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2023-06-14 | — | — | EP | disclosed |
| CN-116075514-A | Pharmacologically active heterocyclic substituted pyrazolo [1,5-a ] pyrimidine derivatives | 吉瑞工厂 | 2023-05-05 | — | — | CN | disclosed |
| US-20230054411-A1 | 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2023-02-23 | — | — | US | disclosed |
| CN-113166158-A | 7-, 8-and 10-substituted aminotriazoloquinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and uses thereof | 默沙东公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10377709-B2 | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-08-13 | — | — | US | disclosed |
| US-20190002406-A1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-01-03 | — | — | US | disclosed |
| US-10071961-B2 | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-09-11 | — | — | US | disclosed |
| WO-2015059212-A1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015037716-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | 住友化学株式会社 (JP) | 2015-03-19 | — | — | WO | disclosed |
| EP-2350061-B1 | 2,3-DISUBSTITUTED PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8357700-B2 | 2,3-disubstituted piperidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20110263643-A1 | 2,3-Disubstituted Piperidine Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-10-27 | — | — | US | disclosed |
| EP-2350061-A1 | 2,3-DISUBSTITUTED PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048016-A1 | 2,3-DISUBSTITUTED PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-29 | — | — | WO | disclosed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | disclosed |
| US-5322852-A | Antitumor, antiprotozoa agents | CIBA-GEIGY CORP. (US) | 1994-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002406-A1 | CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HCCS, XDH, NR1H4 | MAPT 3582/4885PKM 2105/4885MEN1 1901/4885 |
| US-10071961-B2 | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | HCCS, NR1H4, GLS2 | MAPT 3521/4885PKM 2159/4885MEN1 1976/4885 |
| US-10377709-B2 | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | HCCS, XDH, NR1H4 | MAPT 3582/4885PKM 2105/4885MEN1 1901/4885 |
| US-20230054411-A1 | 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA3 | MAPT 4540/4885PKM 2849/4885MEN1 3596/4885 |
| US-20110263643-A1 | 2,3-Disubstituted Piperidine Orexin Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | MAPT 960/4885PKM 3692/4885MEN1 2214/4885 |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | GABRA5, GABRA1, P2RX5 | MAPT 1890/4885PKM 1127/4885MEN1 3529/4885 |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, GABRA1, P2RX5 | MAPT 1890/4885PKM 1127/4885MEN1 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.